Ajanta Pharma Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-d4fbe9e8c42156799d567736.pdf

Key Takeaways


Asia Branded Generic: Supply Chain Disruption, Not Demand Destruction

Yogesh Agrawal: "Overall, there is no constraint on the demand side or ability to generate the business of prescriptions. It is just the geopolitical issues which are impacting our supply chain and logistics resulting into this situation."

India Business: Volume-Led Outperformance Across Therapies


US Generic: A Surge That Will Fade, Then a Launch Drought

Yogesh Agrawal: "We are still believing that we should be landing in the range of mid-single digit to upper mid-single digit situation."

Africa Branded Generic: Field-Force Productivity Driving Sustained Momentum


Margins: Gross Margin Peaked, Cost Pressure Building

Arvind Agrawal: "In terms of expenses, I think, the run rate should remain in the range which is there currently. So I don't expect a major increase in the run rate. But hope, I think, as MD sir pointed out that the US business may see some price erosion, etc., because of which there can be some impact. But otherwise, our guidance of 27% for the whole year stands."

Medium-Term Levers: New Geographies and Portfolio Expansion

Yogesh Agrawal: "We are also looking at, I think, going forward, we are looking to enter into some new markets as well which is maybe in Asia, Middle East, and Latin America. So these are the new geographies which will play out in three to five years because we are at a drawing board where we are doing a product selection, filing, and it all plays out in three to five years."

Guidance & Commitments

CommitmentSpecificsTimeline
Asia Branded Generic growthMid-teens to high-teens growth; Q2–Q4 to catch up for Q1 shortfallFY27 full year
Africa Branded Generic growthHigh double-digit growthFY27 full year
Africa Institution business growthHigh double-digit growthFY27 full year
US Generic growthMid-single-digit to upper mid-single-digit growthFY27 full year
India business growthMid-teens growthFY27 full year
Gross margin~78% ±100 bpsFY27 full year
EBITDA margin~27% ±100 bps (excluding forex loss)FY27 full year
R&D expenditure~5% of revenueFY27 full year
Effective tax rate~26%FY27 full year
Capex~INR400 crores (INR300 crores Pitampur expansion, INR100 crores maintenance)FY27 full year
US product launchesMost launches expected in Q4, subject to FDA approvals; none in Q2 or Q3Q4 FY27
US ANDA filingsFive to seven filingsFY27 full year
New geography entryProduct selection and filing underway; payoff in three to five years3–5 year horizon
Interim dividendINR32 per share, total payout ~INR400 croresQ1 FY27 (paid)

Key Metrics

MetricQ1 FY27
Revenue from operations₹1,626 cr, +25% YoY
Gross margin80%, improving ~100 bps over Q4 FY2026; full-year expected around 78% ±100 bps
Adjusted EBITDA (excl. forex loss)₹454 cr, +21% YoY; margin at 28%
EBITDA margin guidance (full-year)~27% ±100 bps, excluding forex loss
Profit after tax₹334 cr, +31% YoY
Effective tax rate25%; full-year expected ~26%
Return on capital employed37% as at end of June 2026
Return on net worth28% as at end of June 2026
India branded business revenue₹509 cr, +24% YoY; 32% of total revenue
India IQVIA growth (MAT June 2026)15% vs IPM growth of 11%
India volume growth4.7%, 40% higher than IPM volume growth of 3.4%
India new product launches8 during the quarter
Asia branded generic revenue₹225 cr, -16% YoY; full-year guidance of mid-teens to high-teens growth
Africa branded generic revenue₹295 cr, +30% YoY; full-year guidance of high double-digit growth
US generic revenue₹487 cr, +57% YoY; full-year guidance of mid-single-digit growth
Africa institution revenue₹49 cr, +17% YoY (phonetic); full-year guidance of high double-digit growth
R&D spend₹66 cr, ~4% of revenue; full-year expected ~5% of revenue
Capital expenditure₹83 cr; full-year expected ~₹400 cr
Interim dividend₹32 per share, total payout ~₹400 cr
Forex loss (other expenses)₹31 cr
Forex gain (other income)₹50 cr
US product launches2 during the quarter; 5–7 filings expected in FY27
India trade generics revenue₹48 cr vs ₹39 cr YoY